UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 45

of 'Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer'

45
TI
Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).
AU
SO
J Clin Oncol. 2016;34S:ASCO #9009.
 
AD